NCT04632303Active, not recruiting
Early Palliative Care for Patients With Advanced Pancreatic Cancer.
Early Palliative Care for Patients With Advanced Pancreatic Cancer (EarlyCarePan).
Source: ClinicalTrials.gov · Last updated 12 Sept 2025
Brief summary (registry, in English)
Pancreatic adenocarcinoma is one of the deadliest cancers. Patients with pancreatic cancer experience marked physical suffering, psychological distress and resource-demanding care at the end-of-life. Therefore, an urgent need exists to evaluate the early specialized palliative care model in a comparative study and across multiple care settings to define quality of life and survival benefits in patients with pancreatic cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- First submitted
- 13 Nov 2020
- Start date
- 23 Jun 2021
- Primary completion date
- 7 Nov 2024
- Lead sponsor
- Inna Chen, MD
- Diseases
- Pancreatic cancer
- NCT number
- NCT04632303
What you commit to
- Study type: Interventional
- Planned participants: 250
- From 23 Jun 2021 to the primary completion date, 7 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who are already receiving care from the palliative care service are not eligible for participation in the study
Other illness
- Any medical condition that the Investigator considers significant to compromise the safety of the patient or that impairs the interpretation of study assessments
Other
- Exhibiting signs of overt psychopathology or cognitive dysfunction
- Patient participating in another interventional study during the surveillance period. This is only relevant for studies that might interfere with the intervention. Participation in protocols related only to treatment will not preclude participation in the present study. Cases of doubt will be settled by the protocol responsible.
Who the study is looking for
- Adult males and females (aged 18 and over)
- Confirmed by cytology or histology incurable PDAC who are planned to receive medical care for cancer in the first-line setting at the enrolling institution within ≤ 2 weeks
- Written informed consent before any study procedures
- Performance status: ECOG 0-2
- Ability to read and respond to questions or able to complete questions with minimal assistance required from an interpreter or family member
- Planning to receive all medical care for cancer at the enrolling institution.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Herlev & Gentofte University Hospital, Denmark Coordinator of this site? Confirm its status | Herlev | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.